Genetic engineers can design and assemble sophisticated gene circuits to program cells with new functions, but important signaling molecules can become diluted as these cells grow and divide, causing ...
MIDDLETON, Mass., Nov. 6, 2025 /PRNewswire/ -- MavriX Bio, a clinical-stage biotechnology company focused on the development of transformative genetic therapies for Angelman syndrome (AS), today ...
Uniqure NV is regrouping after a surprise switcheroo by the havoc-beset U.S. FDA regarding phase I/II studies with AMT-130 vs. external control in Huntington’s disease (HD) – news of which pushed down ...
Bio-Gene Technology (ASX: BGT) has secured a partnership with world leading chemical company BASF, with the duo planning to develop Bio-Gene’s Flavocide technology for use is stored grain pest control ...
AI-powered vector design and preclinical validation mark the first step in a multi-phase program aimed at accelerating the path from discovery to clinical assessment in Alzheimer's disease. AUSTIN, TX ...
Shortly after taking the reins at BioMarin, CEO Alexander Hardy laid out three paths the company could take for its struggling hemophilia A gene therapy, Roctavian. A year after opting to shrink the ...
BioMarin no longer expects to hit its $4 billion revenue target by 2027, citing various market factors such as impending competition for achondroplasia therapy Voxzogo and the divestment of the gene ...
Oct 27 (Reuters) - BioMarin Pharmaceutical (BMRN.O), opens new tab said on Monday it plans to divest its gene therapy, a product once expected to be a blockbuster treatment for a type of rare bleeding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback